Patents by Inventor Paul VINK

Paul VINK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220135677
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: SAIROPA B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220135671
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 5, 2022
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • Anti-SIRP? antibodies
    Patent number: 10851164
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: December 1, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Erik Voets, Paul Vink, David Lutje Hulsik
  • Anti-HCTLA-4 antibodies
    Patent number: 10808030
    Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: October 20, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20180312587
    Abstract: The present invention relates to anti-SIRP antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: April 13, 2018
    Publication date: November 1, 2018
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • NEW ANTI-HCTLA-4 ANTIBODIES
    Publication number: 20180037654
    Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 8, 2018
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Joost KREIJTZ, David Lutje HULSIK, Paul VINK